Related Experiment Video
Updated: Jun 21, 2026
13:47
Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
Published on: June 3, 2018
CYP1B1, a developmental gene with a potential role in glaucoma therapy.
D Choudhary1, I Jansson, J B Schenkman
1Department of Cell Biology, University of Connecticut Health Center, Farmington, CT 06030, USA.
Summary
Mutations in the CYP1B1 gene are linked to primary congenital glaucoma and other eye disorders. Stem cell therapy offers a potential treatment for these CYP1B1-related glaucomas.
Area of Science:
- Ophthalmology
- Genetics
- Regenerative Medicine
Background:
- The CYP1B1 gene is associated with primary congenital glaucoma (PCG).
- CYP1B1 mutations are implicated in various glaucoma forms and anterior segment disorders, indicating a broad role in ocular physiology.
- Abnormalities in the anterior chamber angle and trabecular meshwork are observed in PCG.
Purpose of the Study:
- To explore the role of CYP1B1 in ocular development and glaucoma pathogenesis.
- To investigate the potential of stem cell therapy for CYP1B1-related glaucomas.
Main Methods:
- Histochemical studies on eyes from PCG individuals.
- Analysis of CYP1B1 gene mutations and their functional impact.
- Review of stem cell research for therapeutic applications.
Main Results:
- CYP1B1 mutations affect trabecular meshwork development, crucial for aqueous humor drainage.
- CYP1B1, a monooxygenase, likely regulates essential endobiotic compounds for filtering structure development.
- Stem cell research presents a promising avenue for treating glaucomas caused by CYP1B1 defects.
Conclusions:
- CYP1B1 plays a critical role in the development of the eye's filtering apparatus.
- Stem cell transplantation with wild-type CYP1B1 offers a potential future therapy for specific glaucomas.
Related Concept Videos
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...